The goal of this project is to evaluate how maternal use of antidepressants and/or anxiolytic medication during pregnancy may have long-lasting consequences on a child’s neurocognitive development. The overall use of prescription medication (particularly antidepressants) by pregnant women has increased steadily over the past three decades. These medications are able to pass the placental barrier and are secreted in breast milk, which raises concerns about adverse effects on a child’s neurodevelopment. Additionally, maternal mood directly influences fetal and infant development through biological, genetic and indirect environmental mechanisms. Therefore, the benefits and risks of receiving pharmacological treatment during pregnancy must be assessed on an individual basis. Recent studies have demonstrated an increase risk in neurodevelopmental disorders such as autism spectrum disorders (ASD) and attention-deficit hyperactivity disorder (ADHD) when exposed to antidepressants prenatally. However, very little research has explored possible effects of prenatal exposure on the developmental trajectory of cognitive skills and language/communication abilities. To date, no studies have explored possible interactions between medication exposure and genetic factors in these cases.